HS-201 (Solid Malignancies) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see how much of the study drug (an imaging agent called HS-201) is needed to mark cancer cells and help doctors to see cancer during and after surgery.

What is the Condition Being Studied?

Solid Malignancies (cells with cancer)

Who Can Participate in the Study?

-Adults
-Diagnosis of a solid malignancy
-Planned surgical removal or biopsy of cancerous cells

Age Group
Adults

What is Involved?

If you choose to join this study you will:
-Have the the study drug (HS-201) given into your vein the day before your surgery.
-Have a small amount of tissue taken out during your surgery

One month after your surgery you will:
-Have a physical exam
-Answer questions about how you are feeling after your surgery
-Give blood samples

Study Details

Full Title
A PHASE I STUDY OF HS-201, AN HSP90 INHIBITOR-LINKED VERTEPORFIN FOR DETECTION OF SOLID MALIGNANCIES
Principal Investigator
H. KimLyerly
Protocol Number
IRB: PRO00102188
NCT: NCT03906643
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698